Becton, Dickinson and Company
Becton, Dickinson and Company (BD) is a global medical technology leader that develops, manufactures, and sells a comprehensive range of medical supplies, devices, laboratory equipment, and diagnostic products. The company focuses on improving medication management, patient safety, and clinical outcomes through advanced solutions for healthcare providers, researchers, and the pharmaceutical industry.
Financials
Based on Q1 2026 · FQ2 FY2026 filing
Revenue
View metricGross Profit
View metricNet Income
View metricOperating Cash Flow
View metricFree Cash Flow
View metricEPS (Diluted)
View metricBusiness Segments
Medical
primaryFocuses on solutions that improve medication management and patient safety across the care continuum, including drug delivery and anesthesia care.
BD Alaris, BD Pyxis, BD Nexiva, BD PosiFlush, BD Hypak
Healthcare institutions, Physicians, Pharmaceutical industry, General public
Life Sciences
majorProvides products for the safe collection and transport of diagnostic specimens, as well as instruments and reagents for infectious disease and cancer diagnosis and cellular research.
BD Vacutainer, BD FACSLyric, BD MAX, BD BACTEC, BD Horizon
Clinical laboratories, Life science researchers, Academic institutions, Hospitals
Interventional
majorDevelops and manufactures vascular, urology, oncology, and surgical specialty products used in interventional procedures.
BD Venovo, BD Lutonix, BD PureWick, BD Phasix, BD Bard
Hospitals, Surgical centers, Specialty clinics
Segment Financials
Medical Essentials — Segment Research and Development as a Percent of Revenues
View metricMedical — Segment, Expenditure, Addition to Long-Lived Assets
View metricMedical Essentials — Segment Cost of Products and Services Sold as a Percent of Revenues
View metricBioPharma Systems — Segment Research and Development as a Percent of Revenues
View metricBioPharma Systems — Segment Cost of Products and Services Sold as a Percent of Revenues
View metricBioPharma Systems — Segment Operating Income (Loss) as a Percent of Revenues
View metricInterventional — Segment Research and Development as a Percent of Revenues
View metricInterventional — Segment Cost of Products and Services Sold as a Percent of Revenues
View metricInterventional — Segment Operating Income (Loss) as a Percent of Revenues
View metricBusiness Overview
Competitive Position
A global leader in medical technology with a dominant position in medication delivery and diagnostic specimen collection.
Geographies
North America, Europe, Asia-Pacific, Latin America
Customer Segments
Hospitals, Clinical Laboratories, Pharmaceutical Companies, Research Institutions
Upstream Dependencies
Raw material suppliers (plastics, resins, metals), Electronic component manufacturers, Specialized chemical and reagent suppliers
Downstream Customers
Acute care hospitals, Reference laboratories, Retail pharmacies, Government health agencies
Competitors & Partners
Competitors
Danaher
DHR
Competitor in life sciences and diagnostics
Abbott
ABT
Competitor in medical devices and diagnostics
Thermo Fisher Scientific
TMO
Competitor in laboratory equipment and life sciences research
Medtronic
MDT
Competitor in interventional and surgical products
Baxter International
BAX
Competitor in medication delivery and infusion systems
Subsidiaries
C. R. Bard
Acquired entity forming the core of the Interventional segment
CareFusion
Acquired entity specializing in medication management and patient safety
Becton, Dickinson and Company FAQ
Common questions about Becton, Dickinson and Company
Becton, Dickinson and Company (BD) is a global medical technology leader that develops, manufactures, and sells a comprehensive range of medical supplies, devices, laboratory equipment, and diagnostic products. The company focuses on improving medication management, patient safety, and clinical outcomes through advanced solutions for healthcare providers, researchers, and the pharmaceutical industry.
Becton, Dickinson and Company (BDX) has a market capitalization of $39.8B and trades on NYSE.
Becton, Dickinson and Company generated $22.2B in trailing twelve-month revenue with net income of $1.1B, representing a net margin of 5.1%. Gross margin stands at 46.9%, with free cash flow of $3.5B. These figures are based on the Q1 2026 filing.
Becton, Dickinson and Company's key competitors include Danaher, Abbott Laboratories, Thermo Fisher Scientific, and others. These companies compete in similar markets and product categories.
Becton, Dickinson and Company has approximately 73,000 employees.